Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
surgery to prevent SSI.11,12 The retraction of several trials has raised further concerns regarding the evidence base.13 The COVID-19 pandemic has highlighted the importance of oxygen as a scarce health-care resource, emphasising the need to establish the evidence for the recommendation for liberal inspired oxygen to prevent SSI. This issue is being addressed in another large pragmatic trial (PERIoperative respiratory care and outcomes for patients Undergoing high risk abdominal surgery [PENGUIN], NCT04256798) also led by the NIHR Global Health Research Unit on Global Surgery.

The work by the NIHR Global Health Research Unit on Global Surgery has answered (through the FALCON trial) and is answering (through the PENGUIN trial) important questions relating to appropriate and cost-effective interventions for SSI in low-resource environments. These data will improve care and allow proper allocation of scarce resources.

BMB is a co-principal investigator of the NIHR Global Health Research Unit on Global Surgery PENGUIN trial. BMB received financial support to attend the NIHR Global Health Research Unit on Global Surgery meetings in Ghana in 2019, Rwanda in 2018, and South Africa in 2017. VM and ALS declare no competing interests.

*Bruce M Biccard, Vanessa Msosa, Ahmadou L Samateh
bruce.biccard@uct.ac.za

Department of Anaesthesia and Perioperative Medicine, Groote Schuur Hospital, Faculty of Health Sciences, University of Cape Town, Cape Town 7935, South Africa (BMB); Kamuzu Central Hospital, Lilongwe, Malawi (VM); School of Medicine and Allied Health Sciences, University of The Gambia, Banjul, The Gambia (ALS)

Depression and anxiety disorders during the COVID-19 pandemic: knowns and unknowns

The COVID-19 pandemic has taken a toll on people’s mental health. Yet, the global extent of this impact remains largely unknown. By leveraging the best available data from surveys around the world with measurements of anxiety and depression both before and during the pandemic, and analysing these data using the Global Burden of Disease Study (GBD) model, the COVID-19 Mental Disorders Collaborators’ provide global insight into the burden of depression and anxiety disorders during the pandemic to date. The authors estimated a significant increase in the prevalence of both major depressive disorder (with an estimated additional 53·2 million [95% uncertainty interval 44·8–62·9] cases worldwide—ie, a 27·6% [25·1–30·3] increase) and anxiety disorders (76·2 million [64·3–90·6] additional cases—ie, a 25·6% [23·2–28·0] increase) since before the pandemic. Increased prevalence was seen for both males and females across the lifespan. These findings are all the more concerning because depressive and anxiety disorders were already leading causes of disability worldwide.7

The study has unique strengths. First, by using the GBD model, it translates crude estimates from heterogeneous surveys into numbers of additional cases and disability-adjusted life-years. This makes the findings more tangible for policy makers, academics, charities, and the general public. Second, the study leverages data on COVID-19 impact indicators (ie,
human mobility, SARS-CoV-2 infection rates, and excess mortality). The COVID-19 Mental Disorders Collaborators estimated these indicators for all countries and territories and used them to inform the extrapolation of changes in prevalence to countries with no available survey data. Furthermore, the authors assessed the generalisability of their estimates for countries with no available surveys using a leave-one-country-out cross-validation approach, in which changes in prevalence were estimated using the GBD model as if survey data for one country were not available and the prediction was then compared with the actual survey data.

The study also has a few key limitations, largely resulting from the available data rather than the approach used to analyse them. First, direct measurements on changes in prevalence of depressive and anxiety disorders are not available in large regions of the world (eg, within South America and Africa). For these regions, the GBD model has to extrapolate estimates from other regions (eg, the USA or Europe), which are very different on many levels (economically, demographically, politically, and culturally). This extrapolation might be unreliable, as shown in the cross-validation results. For instance, the GBD model predicts a substantial increase in the prevalence of major depressive disorder in Denmark and almost no change in China whereas the opposite is observed in surveys (appendix of Article [p 24]). Second, most of the available data are based on self-report scales (eg, Patient Health Questionnaire-9 or General Anxiety Disorder-7 [GAD-7]), which measure symptoms rather than actual diagnoses. Although both symptoms and diagnoses are important, the difference between them is relevant in the pandemic context. A diagnosis of anxiety disorder according to the tenth International Classification of Diseases and Related Health Problems requires that individuals recognise their emotional distress as excessive or unreasonable. GAD-7 does not capture this aspect. For an individual at high risk of COVID-19 complications to constantly feel nervous and afraid would not be unreasonable (hence, not meeting requirements for an anxiety disorder), yet it would yield a high GAD-7 score. Finally, the study is unable to identify what is causing the increased burden of major depressive disorder and anxiety. In particular, the relative contributions to the prevalence of depression and anxiety disorders of direct consequences of COVID-19 illness, some measures used to curb the propagation of the virus (eg, lockdowns), and other correlates of the pandemic (eg, economic austerity) remain elusive.

By synthesising the best available data, this study not only reveals what we do know, but also—crucially—exposes what we still do not know. These known unknowns have implications for interpretation of the findings. The paucity of direct measurements in most countries implies that the findings are unable to inform on specific countries that have been more affected than others. Aid programmes aimed at improving population mental health are clearly needed widely, and this study is unable to suggest specific countries to be targeted first. Measurement of clinical diagnoses will be needed to plan service provision, ascertain the burden of the pandemic in terms of mental disorders, and forecast social and economic consequences. Crucially, identifying causal mechanisms, and modifiable mechanisms in particular, will be important to design and deliver the right interventions to the right people.

The findings of this study should urgently incentivise more research to determine the fuller geographical distribution of depression and anxiety disorders, the prevalence of depressive and anxiety disorders, and the underpinning mechanisms to improve mental health in the context of the COVID-19 pandemic globally.

We declare no competing interests.

*Maxime Taquet, Emily A Holmes, Paul J Harrison
maxime.taquet@psych.ox.ac.uk

Department of Psychiatry, University of Oxford, Oxford, OX3 7JX, UK (MT, PJH); Oxford Health NHS Foundation Trust, Oxford, UK (MT, PJH); Department of Psychology, Uppsala University, Uppsala, Sweden (EAH); Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden (EAH)

1 COVID-19 Mental Disorders Collaborators. Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. Lancet 2021; published online Oct 8. https://doi.org/10.1016/S0140-6736(21)02143-7
2 Murray CJL, Vos T, Lozano R, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012, 380: 2197–223.
3 Taquet M, Geddes JR, Husain M, Luciano S, Harrison PJ. 6-month neurological and psychiatric outcomes in 236 279 survivors of COVID-19: a retrospective cohort study using electronic health records. Lancet Psychiatry 2021, 8: 416–27.
4 Marroquin B, Vine V, Morgan R. Mental health during the COVID-19 pandemic: effects of stay-at-home policies, social distancing behavior, and social resources. Psychiatry Res 2020, 293: 113419.
5 Holmes EA, O’Connor RC, Perry VH, et al. Multidisciplinary research priorities for the COVID-19 pandemic: a call for action for mental health science. Lancet Psychiatry 2020, 7: S47–60.